GlassScriptPhysician profile
Jennifer D Bernt
NPI 1336641463
$7,660.13
in general payments reported to CMS, 2019-2025
46 companies · $2,402 in 2025
The $2,402 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $886 · 2023: $1,860 · 2024: $1,765 · 2025: $2,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,415 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,414.83 |
| Education | $612.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $983.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $877.18 | 2022-2025 | Enhertu, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $614.41 | 2021-2025 | Carvykti, Rybrevant, Tecvayli |
| Astellas Pharma US INC | $455.08 | 2021-2025 | Vyloy, Xtandi |
| Celgene Corporation | $362.85 | 2021-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $352.46 | 2021-2025 | |
| Abbvie INC. | $277.64 | 2024-2025 | |
| Daiichi Sankyo INC. | $267.37 | 2023-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $250.79 | 2021-2025 | Trodelvy |
| Incyte Corporation | $215.69 | 2021-2025 | Jakafi |
| Seagen INC. | $203.94 | 2021-2023 | Padcev |
| Eisai INC. | $174.18 | 2021-2024 | |
| Glaxosmithkline, LLC. | $165.60 | 2021-2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $143.36 | 2023-2024 | Fotivda |
| Blueprint Medicines Corporation | $141.83 | 2023-2024 | Ayvakit |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $135.55 | 2024-2025 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $135.34 | 2025 | Opdivo, Reblozyl, Opdualag |
| Mirati Therapeutics, INC. | $128.23 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $128.07 | 2023-2025 | Libtayo |
| Progenics Pharmaceuticals, INC. | $125.00 | 2024 | |
| Merck Sharp & Dohme LLC | $122.22 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Karyopharm Therapeutics INC. | $118.47 | 2024-2025 | Xpovio |
| Amgen INC. | $117.29 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Pharmacyclics LLC, An Abbvie Company | $107.46 | 2021-2023 | Imbruvica, Epkinly |
| Rigel Pharmaceuticals, INC. | $93.94 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $91.38 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Genzyme Corporation | $85.14 | 2021-2024 | |
| Aspira Women'S Health INC | $77.29 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $73.69 | 2023-2025 | Onivyde, Tazverik |
| Lilly USA, LLC | $69.53 | 2021-2025 | Jaypirca, Retevmo, Verzenio |
| Genentech USA, INC. | $69.20 | 2022-2023 | Perjeta, Venclexta, Phesgo |
| Cti Biopharma Corp. | $58.99 | 2023 | Vonjo |
| Tersera Therapeutics LLC | $56.06 | 2024-2025 | Zoladex |
| Taiho Oncology, INC. | $48.21 | 2023 | |
| Stemline Therapeutics INC. | $47.43 | 2023-2024 | Orserdu |
| Array Biopharma INC | $42.07 | 2021-2024 | Braftovi, Lorbrena, Xalkori |
| Sobi, INC | $38.01 | 2025 | |
| Kite Pharma, INC. | $37.80 | 2022-2023 | |
| Adc Therapeutics America, INC. | $34.90 | 2023 | |
| Sun Pharmaceutical Industries INC. | $27.99 | 2023 | Odomzo, Yonsa |
| Genmab U.S., INC. | $27.48 | 2023 | Tivdak |
| Tempus Ai, INC | $19.45 | 2024 | |
| Puma Biotechnology, INC. | $16.25 | 2023 | |
| Pharmaessentia USA Corporation | $15.38 | 2025 | Besremi |
| Beigene USA, INC. | $13.39 | 2023 | Brukinsa |
| Janssen Pharmaceuticals, INC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bernt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.